Anti-obesity Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Anti-obesity Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of Anti-obesity Drugs Market

The anti-obesity drugs market size was valued at USD 4.51 billion in 2023, and the market is now projected to grow from USD 6.15 billion in 2024 to USD 37.94 billion by 2032, exhibiting a CAGR of 25.5% during the forecast period of 2024-2032.

Pandemic slowed anti-obesity drugs market growth. In 2020, the growth ended up impeded via fewer in-person visits to healthcare specialists and the closure of non-critical services. In 2021, telemedicine and online pharmacies reduced the terrible impact on the market with the useful resource of converting in-man or woman health facility visits with repeat prescriptions. Following the pandemic, the enterprise grew due to easier COVID-19 regulations and growing weight problems charges globally. The market is anticipated to develop drastically because of new product releases and robust pipelines from key players.

Obesity has end up a international epidemic, causing as a minimum 2.8 Mil deaths every year, in step with WHO figures. As obesity costs rise, there could be a more need for effective treatment alternatives to address the contamination. As weight problems will become greater commonplace in the destiny, there will be a developing need for novel anti-weight problems remedies in the worldwide market. To meet the need for anti-obesity medicinal drugs, main and developing agencies have released R&D activities.

Obesity has end up an epidemic because of its widespread upward push in occurrence over latest a long time. Obesity is a primary public fitness challenge because it raises the hazard of continual ailments such kind 2 diabetes, cardiovascular ailment, high blood stress, and cancer. This has multiplied public know-how of excessive chronic contamination prevention through appropriate motion plans.

Comprehensive Analysis of Anti-obesity Drugs Market

The global anti-obesity drugs market is classified into prescribed drugs and over-the-counter pills. Prescription drugs dominate the marketplace because of key players investing in R&D and strategic partnerships. Healthcare professionals' prescriptions additionally raise income. The marketplace is split into clinic pharmacy, retail, and online pharmacy. Retail and online pharmacy are predicted to generate the best revenue in 2023 due to increased usage of e-pharmacies platforms and the provision of anti-obesity capsules. Obesity is a persistent circumstance, and sufferers need refills for lengthy-term treatment, leading to more adoption of anti-obesity drugs thru these channels.

The North America region lead the anti-obesity drugs market share by benefitting a market size of USD 1.91 billion in 2023 due to rapid expansion can be linked to high obesity rates in high-income nations with high healthcare costs per person. According to 2021 research released by the National Library of Medicine, people with obesity in the United States incur high yearly medical care expenses of USD 2,505. These costs rise dramatically with obesity class, from 68.4% for sophistication 1 to 233.6% for class three.

The market is concentrated, with some key organizations controlling a sizeable part of it. Novo Nordisk A/S is a market chief with a robust product variety and recent regulatory approvals that improve increase. In June 2021, Novo Nordisk A/S had been given FDA clearance for Wegovy, a treatment for persistent weight manipulates in humans with weight problems or obese and at the least one weight-related comorbidity. The commercial corporation expects advanced income of Wegovy, an obesity drug, in 2024 in comparison to 2023.

In November 2023, Lilly reported that Zepbound has been approved by the United States Food and Drug Administration to manage persistent weight in obese individuals.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2032

Base Year 2023

Estimated Year 2024

Forecast Period 2024-2032

Historical Period 2019-2022

Growth Rate CAGR of 25.5% from 2024 to 2032

Unit Value (USD billion)

Segmentation

By Type

Prescription Drugs

OTC Drugs

By Distribution Channel

Hospital Pharmacy

Retail and Online Pharmacy

By Geography

North America (By Type, By Distribution Channel, By Country)

U.S.

Canada

Europe (By Type, By Distribution Channel, By Country/Sub-Region)

Germany

U.K.

France

Italy

Spain

Scandinavia

Rest of Europe

Asia Pacific (By Type, By Distribution Channel, By Country/Sub-Region)

China

Japan

India

Australia

Southeast Asia

Rest of Asia Pacific

Latin America (By Type, By Distribution Channel, By Country/Sub-Region)

Brazil

Mexico

Rest of Latin America

Middle East & Africa (By Type, By Distribution Channel, By Country/Sub-Region)

GCC

South Africa

Rest of Middle East & Africa


Please Note: It will take 5-6 business days to complete the report upon order confirmation.